Literature DB >> 32590406

Opioid Receptor μ-1 and Ketamine Effects in a Suicidal Depression Trial: A Post Hoc Exploration.

Michael F Grunebaum, Hanga C Galfalvy, Jun Liu, Yung-Yu Huang, Stephen Marcott, Ainsley K Burke, J John Mann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32590406      PMCID： PMC7347432          DOI： 10.1097/JCP.0000000000001237

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN： 0271-0749            Impact factor:   3.118


× No keyword cloud information.
  20 in total

1.  Influence of OPRM1 Asn40Asp variant (A118G) on [11C]carfentanil binding potential: preliminary findings in human subjects.

Authors:  Elise M Weerts; Mary E McCaul; Hiroto Kuwabara; Xiaoju Yang; Xiaoqiang Xu; Robert F Dannals; J James Frost; Dean F Wong; Gary S Wand
Journal:  Int J Neuropsychopharmacol       Date:  2012-03-08       Impact factor: 5.176

2.  Caution Against Overinterpreting Opiate Receptor Stimulation as Mediating Antidepressant Effects of Ketamine.

Authors:  Gerard Sanacora
Journal:  Am J Psychiatry       Date:  2019-03-01       Impact factor: 18.112

3.  Explaining Naltrexone's Interference With Ketamine's Antidepressant Effect.

Authors:  Michael Wang; Adam Kaplin
Journal:  Am J Psychiatry       Date:  2019-05-01       Impact factor: 18.112

4.  Genetic variation in the behavioral effects of buprenorphine in female mice derived from a murine model of the OPRM1 A118G polymorphism.

Authors:  Caroline A Browne; Rebecca L Erickson; Julie A Blendy; Irwin Lucki
Journal:  Neuropharmacology       Date:  2017-02-07       Impact factor: 5.250

5.  Effects of the Mu opioid receptor polymorphism (OPRM1 A118G) on pain regulation, placebo effects and associated personality trait measures.

Authors:  Marta Peciña; Tiffany Love; Christian S Stohler; David Goldman; Jon-Kar Zubieta
Journal:  Neuropsychopharmacology       Date:  2014-10-13       Impact factor: 7.853

Review 6.  Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.

Authors:  Panos Zanos; Ruin Moaddel; Patrick J Morris; Lace M Riggs; Jaclyn N Highland; Polymnia Georgiou; Edna F R Pereira; Edson X Albuquerque; Craig J Thomas; Carlos A Zarate; Todd D Gould
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

7.  Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts.

Authors:  Tae-Hwi Schwantes-An; Juan Zhang; Li-Shiun Chen; Sarah M Hartz; Robert C Culverhouse; Xiangning Chen; Hilary Coon; Josef Frank; Helen M Kamens; Bettina Konte; Leena Kovanen; Antti Latvala; Lisa N Legrand; Brion S Maher; Whitney E Melroy; Elliot C Nelson; Mark W Reid; Jason D Robinson; Pei-Hong Shen; Bao-Zhu Yang; Judy A Andrews; Paul Aveyard; Olga Beltcheva; Sandra A Brown; Dale S Cannon; Sven Cichon; Robin P Corley; Norbert Dahmen; Louisa Degenhardt; Tatiana Foroud; Wolfgang Gaebel; Ina Giegling; Stephen J Glatt; Richard A Grucza; Jill Hardin; Annette M Hartmann; Andrew C Heath; Stefan Herms; Colin A Hodgkinson; Per Hoffmann; Hyman Hops; David Huizinga; Marcus Ising; Eric O Johnson; Elaine Johnstone; Radka P Kaneva; Kenneth S Kendler; Falk Kiefer; Henry R Kranzler; Ken S Krauter; Orna Levran; Susanne Lucae; Michael T Lynskey; Wolfgang Maier; Karl Mann; Nicholas G Martin; Manuel Mattheisen; Grant W Montgomery; Bertram Müller-Myhsok; Michael F Murphy; Michael C Neale; Momchil A Nikolov; Denise Nishita; Markus M Nöthen; John Nurnberger; Timo Partonen; Michele L Pergadia; Maureen Reynolds; Monika Ridinger; Richard J Rose; Noora Rouvinen-Lagerström; Norbert Scherbaum; Christine Schmäl; Michael Soyka; Michael C Stallings; Michael Steffens; Jens Treutlein; Ming Tsuang; Tamara L Wall; Norbert Wodarz; Vadim Yuferov; Peter Zill; Andrew W Bergen; Jingchun Chen; Paul M Cinciripini; Howard J Edenberg; Marissa A Ehringer; Robert E Ferrell; Joel Gelernter; David Goldman; John K Hewitt; Christian J Hopfer; William G Iacono; Jaakko Kaprio; Mary Jeanne Kreek; Ivo M Kremensky; Pamela A F Madden; Matt McGue; Marcus R Munafò; Robert A Philibert; Marcella Rietschel; Alec Roy; Dan Rujescu; Sirkku T Saarikoski; Gary E Swan; Alexandre A Todorov; Michael M Vanyukov; Robert B Weiss; Laura J Bierut; Nancy L Saccone
Journal:  Behav Genet       Date:  2015-09-21       Impact factor: 2.805

8.  Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism.

Authors:  Nolan R Williams; Boris D Heifets; Christine Blasey; Keith Sudheimer; Jaspreet Pannu; Heather Pankow; Jessica Hawkins; Justin Birnbaum; David M Lyons; Carolyn I Rodriguez; Alan F Schatzberg
Journal:  Am J Psychiatry       Date:  2018-08-29       Impact factor: 18.112

9.  Ultra-Low-Dose Buprenorphine as a Time-Limited Treatment for Severe Suicidal Ideation: A Randomized Controlled Trial.

Authors:  Yoram Yovell; Gali Bar; Moti Mashiah; Yehuda Baruch; Irina Briskman; Jack Asherov; Amit Lotan; Amihai Rigbi; Jaak Panksepp
Journal:  Am J Psychiatry       Date:  2015-12-18       Impact factor: 18.112

Review 10.  OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models.

Authors:  Stephen D Mague; Julie A Blendy
Journal:  Drug Alcohol Depend       Date:  2010-01-13       Impact factor: 4.492
View more
  3 in total

1.  Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis.

Authors:  Gustavo C Medeiros; Todd D Gould; William L Prueitt; Julie Nanavati; Michael F Grunebaum; Nuri B Farber; Balwinder Singh; Sudhakar Selvaraj; Rodrigo Machado-Vieira; Eric D Achtyes; Sagar V Parikh; Mark A Frye; Carlos A Zarate; Fernando S Goes
Journal:  Mol Psychiatry       Date:  2022-06-27       Impact factor: 15.992

2.  Abnormal expression profile of plasma-derived exosomal microRNAs in patients with treatment-resistant depression.

Authors:  Lian-Di Li; Muhammad Naveed; Zi-Wei Du; Huachen Ding; Kai Gu; Lu-Lu Wei; Ya-Ping Zhou; Fan Meng; Chun Wang; Feng Han; Qi-Gang Zhou; Jing Zhang
Journal:  Hum Genomics       Date:  2021-08-21       Impact factor: 4.639

3.  Ketamine vs midazolam: Mood improvement reduces suicidal ideation in depression.

Authors:  Annabella Hochschild; John G Keilp; Sean P Madden; Ainsley K Burke; J John Mann; Michael F Grunebaum
Journal:  J Affect Disord       Date:  2021-12-22       Impact factor: 4.839
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.